Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon4 and 2 bp deletion in exon4.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-DHX58, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DHX58 also known as LGP2 is a member of the RIG-I-like receptor (RLR) family. It has an important role in the immune response against viral infections. This protein weighs approximately 73 kDa. DHX58 lacks the caspase activation and recruitment domains found in other RLRs which distinguishes its function. It expresses in multiple tissues including the spleen and peripheral blood leukocytes where it contributes to the detection of viral RNA.
Biological function summary
DHX58 functions as a regulatory molecule in innate immunity. It usually does not act alone and can form complexes with other RLRs like RIG-I and MDA5. These complexes enhance antiviral signal transduction by modulating downstream components of the interferon signaling pathway. By influencing these pathways DHX58 contributes to the regulation of the immune response ensuring the proper activation of antiviral defense mechanisms.
Pathways
Several immune pathways involve DHX58 namely the RIG-I-like receptor signaling pathway and the interferon regulatory pathways. These pathways are critical for maintaining the body's defense against viral infections. Within these pathways DHX58 interacts with related proteins such as RIG-I and MDA5 which are important for recognizing viral RNA and facilitating subsequent immune responses.
Research suggests that alterations in DHX58 function can link to autoimmune disorders such as systemic lupus erythematosus (SLE) and viral infections. The target's proper regulation is essential to prevent inappropriate immune activation which might lead to such conditions. In these contexts proteins like RIG-I and MDA5 frequently interact with DHX58 influencing the disease outcomes and severity.
